Physician profile
Tom H Sun
NPI 1306803283
$5,036.21
in general payments reported to CMS, 2019-2025
22 companies · $1,003 in 2025
The $1,003 reported for 2025 was more than what 77% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $827 · 2020: $339 · 2021: $675 · 2022: $757 · 2023: $957 · 2024: $478 · 2025: $1,003.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,399 · Honoraria: $38.86.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,399.32 |
| Honoraria | $38.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,816.45 | 2019-2025 | Rocklatan, Rhopressa, Simbrinza |
| Abbvie INC. | $427.37 | 2022-2024 | Lumigan, Vuity, Alphagan P |
| Aerie Pharmaceuticals, INC. | $350.23 | 2019-2021 | |
| Allergan, INC. | $277.60 | 2020-2022 | |
| Johnson & Johnson Surgical Vision, INC. | $227.40 | 2019-2024 | Tecnis Iol |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $214.96 | 2019-2021 | |
| Glaukos Corporation | $206.19 | 2023 | |
| Astellas Pharma US INC | $196.92 | 2025 | Izervay |
| Rxsight INC | $181.03 | 2023-2025 | Rxsight Contact Lens, Rxsight Light Delivery Device (Ldd), Rxsight Injector Cartridge |
| Horizon Therapeutics Plc | $176.88 | 2020-2023 | Tepezza |
| Tarsus Pharmaceuticals, INC. | $170.75 | 2025 | Xdemvy |
| Oyster Point Pharma, INC. | $161.11 | 2022-2023 | Tyrvaya |
| Amgen INC. | $152.09 | 2025 | Tepezza |
| Biotissue Holdings INC. | $123.61 | 2022 | |
| Bausch & Lomb Americas INC. | $112.58 | 2023-2024 | Miebo, Toric |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Thea Pharma INC. | $72.71 | 2024-2025 | Iyuzeh |
| Merz North America, INC. | $59.22 | 2019-2020 | |
| Dompe US, INC. | $28.57 | 2025 | Oxervate |
| Celularity INC. | $21.47 | 2021 | |
| Kala Pharmaceuticals, INC. | $21.01 | 2021 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Rayner Intraocular Lenses Limited | $18.66 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tom Sun listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.